Sponsored Symposia

Friday 24th November

Breakfast Sessions

Optimising patient outcomes in COPD – management in 2017 and beyond
Sponsored by Boehringer Ingelheim

Our management of COPD has changed and improved significantly over time. And this year has been no exception. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy document has undergone a major revision in 2017 – in particular, the proposed assessment and treatment algorithm have been updated. But what has led to these changes, and why? And are we any closer to reaching our ultimate goal of providing a highly individualised approach to COPD management? The expert panel will discuss, and provide some answers to these key questions.

0700-0705 Welcome and Introduction Christine Jenkins
0705-0730 Foundation therapy in COPD: Optimising patient outcomes with the emphasis on reducing future risk David MG Halpin
0730-0750 Add-on therapy in COPD: Defining the role for ICS using an individualised approach Christine Jenkins
0750-0800 Q and A  

 

Lunchtime Sessions

Details to be confirmed

Saturday 25th November

Breakfast Sessions

Evolving treatment strategies in COPD: what’s on the horizon?
Sponsored by Novartis

Chair: David Price
0730-0735 Introduction David Price, Singapore
0735-0755 Shaping the evolution: key evidence driving COPD treatment strategies? Peter Barnes, UK
0755-0810 Can we switch treatment? What's the evidence? Wisia Wedzicha, UK
0810-0825 ICS: the right patient at the right time David Price, Singapore
0825-0830 Summary and close David Price, Singapore
0830-0845 Chair-led expert discussion and audience Q&A All speakers

 

Lunchtime Sessions

Is real world real world?
Sponsored by GSK

 

Treating Small Airways: A step further in Asthma and COPD management
Sponsored by Chiesi

 

Sunday 26th November

Breakfast Sessions

Details to be confirmed

Lunchtime Sessions

Details to be confirmed

Stay up to date

Join the Congress Mailing List

APSR 2017
Go to top